Frontlight ResearchEarly access
Alzheimer disease trials in China
83 of 134 trials · From ClinicalTrials.gov, checked 18 November 2026. Ask the study team whether a trial fits you.
- Phase 1Not yet taking people in ChinaA Study of LY4405094 in Healthy Participants and Participants With Alzheimer's Disease
- Where
- Beijing, Minhang District, Shanghai
- Age
- 18 years to 85 years
- People
- 68 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07787182 · EU 2026-527295-81-00 - Phase 3Taking peopleScreening Study to Determine Individuals With Potential Trial Eligibility for Alzheimer's Disease Studies
- Where
- Beijing, Changchun, Chengdu, Chongqing, Guangzhou, Hefei, Nanjing, Shanghai, Suzhou, Xuzhou
- Age
- 50 years to 90 years
- People
- 80,000 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07177352 - Phase 3Taking peopleOpen-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Kunming, Nanchang, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Wenzhou, Xi'an, Zhenjiang
- Age
- 55 years to 90 years
- People
- 1,000 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT05980949 · EU 2023-504151-27-00 - Phase 3Taking peopleA Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)
- Where
- Beijing, Changsha, Guangzhou, Haidian District, Hangzhou, Kunming, Nanjing, Shenzhen, Tianjin, Xian
- Age
- 55 years to 90 years
- People
- 650 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT06937229 · EU 2024-519994-20-00 - No phaseTaking peopleAcoustic Stimulation During Sleep for Alzheimer's Disease
- Where
- Beijing
- Age
- 60 years to 75 years
- People
- 40
- Run by
- Xuanwu Hospital, Beijing
See details and how to joinNCT07924657 - No phaseNot yet taking people in China40 Hz Audio-Visual Stimulation Therapy for AD
- Where
- Xiamen
- Age
- 50 years to 80 years
- People
- 50
- Run by
- The First Affiliated Hospital of Xiamen University
See details and how to joinNCT07926438 - Phase 3Taking peopleA Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Haidian District, Hangzhou, Kunming, Nanjing, Shanghai, Shenzhen, Tianjin, Xian
- Age
- 55 years to 90 years
- People
- 426 worldwide
- Run by
- Bristol-Myers Squibb
See details and how to joinNCT07011732 · EU 2025-520613-31-00 - Phase 2Taking peopleA Study to Investigate the Safety and Effectiveness of SAR448851 in Participants With Early Alzheimer's Disease
- Where
- Beijing
- Age
- 55 years to 85 years
- People
- 160 worldwide
- Run by
- Sanofi
See details and how to joinNCT07688213 · EU 2025-524581-14-00 - Phase 3Taking peopleA Study of Trontinemab in Cognitively Unimpaired Individuals at Risk for Progression to Symptomatic Alzheimer's Disease
- Where
- Beijing, Changchun, Fuzhou, Guangzhou, Hangzhou, Nanchang, Nanjing, Shanghai, Shijiazhuang, Suzhou, Xi'an, Xianyang
- Age
- 55 years to 80 years
- People
- 1,600 worldwide
- Run by
- Hoffmann-La Roche
See details and how to joinNCT07717411 - Phase 1Not yet taking people in ChinaA Master Protocol Studying Multiple Amyloid-Targeting Therapies in Healthy Participants and Participants With Alzheimer's Disease
- Where
- Beijing, Minhang District, Shanghai
- Age
- 18 years to 85 years
- People
- 179 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07787169 - No phaseTaking peopleNetwork-Guided Individualized TMS for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
- Where
- Hefei
- Age
- 50 years to 90 years
- People
- 40
- Run by
- Anhui Medical University
See details and how to joinNCT07692542 - Phase 2Not yet taking people in ChinaA Phase 2 Clinical Study of Simenafil Hydrochloride Tablets in the Treatment of Alzheimer's Disease
- Where
- Beijing
- Age
- 55 years to 90 years
- People
- 200
- Run by
- Vigonvita Life Sciences
See details and how to joinNCT07905352 - Phase 3Taking peopleA Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
- Where
- Beijing, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Kunming, Nanjing, Ningbo, Shanghai, Shenzhen, Tianjin, Xi'an, Zhenjiang
- Age
- 55 years to 90 years
- People
- 406 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06585787 · EU 2024-516363-92-00 - No phaseEnrolling by invitationBrain Heath Service for Prevention of AD
- Where
- Hong Kong
- Age
- 55 years to 80 years
- People
- 4,000
- Run by
- Chinese University of Hong Kong
See details and how to joinNCT07834528 - Phase 3Taking peopleA Study to Assess Efficacy and Safety of KarXT for the Treatment of Psychosis Associated With Alzheimer's Disease (ADEPT-2)
- Where
- Beijing, Chengdu, Chongqing, Guangzhou, Hangzhou, Hefei, Nanchang, Nanjing, Shanghai, Shenzhen, Tianjin, Wenzhou, Zigong
- Age
- 55 years to 90 years
- People
- 500 worldwide
- Run by
- Karuna Therapeutics, Inc., a Bristol Myers Squibb company
See details and how to joinNCT06126224 · EU 2023-504416-16-00 - Phase 1Not yet taking people in ChinaA Study of LY4560736 in Healthy Participants and Participants With Alzheimer's Disease (AD)
- Where
- Beijing, Minhang District, Shanghai
- Age
- 18 years to 85 years
- People
- 111 worldwide
- Run by
- Eli Lilly and Company
See details and how to joinNCT07843459 - Phase 2Not yet taking people in ChinaStudy to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease
- Where
- Beijing, Hangzhou, Hefei, Nanjing, Shanghai Shi, Wuhan
- Age
- 55 years to 90 years
- People
- 120 worldwide
- Run by
- Celgene
See details and how to joinNCT06808984 - Phase 2Taking peopleTo Evaluate the Safety and Efficacy of RP902 Tablets
- Where
- Beijing
- Age
- 50 years to 85 years
- People
- 360
- Run by
- Risen (Suzhou) Pharma Tech Co., Ltd.
See details and how to joinNCT07579884 - Phase 3Taking peopleNear-infrared Light Therapy Device for Mild-Moderate Alzheimer's Disease (NirsCure-03A)
- Where
- Baotou, Beijing, Hangzhou, Shanghai, Shijiazhuang, Suzhou, Taiyuan, Tianjin, Xi'an, Xi’an
- Age
- 50 years to 85 years
- People
- 320
- Run by
- Danyang Huichuang Medical Equipment Co., Ltd.
See details and how to joinNCT07262645 - No phaseTaking peopleEfficacy and Safety of Photobiomodulation Therapy in Patients With Mild Cognitive Impairment and Mild Alzheimer's Disease
- Where
- Beijing
- Age
- 50 years to 85 years
- People
- 20
- Run by
- Jun Xu
See details and how to joinNCT07835399 - Phase 1/2Taking peopleA Study to Assess the Safety and Effects of ABBV-1758 Following Subcutaneous or Intravenous Injections in Participants With Alzheimer's Disease
- Where
- Beijing, Guangzhou
- Age
- 50 years to 90 years
- People
- 210 worldwide
- Run by
- AbbVie
See details and how to joinNCT07599670 - No phaseTaking peopleTranscranial Random Noise (tRNS) for BPSD in Alzheimer's Disease: A Double-blind Randomized Controlled Trial
- Where
- Hefei
- Age
- 45 years to 84 years
- People
- 40
- Run by
- Anhui Medical University
See details and how to joinNCT07827196 - No phaseTaking peopleEfficacy and Safety of Transcranial Magnetic Stimulation in Treatment of Alzheimer's Disease
- Where
- Fuzhou
- Age
- 50 years to 90 years
- People
- 81
- Run by
- Fujian Medical University Union Hospital
See details and how to joinNCT07324161 - Phase 3Taking peopleDonanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
- Where
- Beijing, Changchun, Changsha, Chengdu, Chongqing, Fuzhou, Guangzhou, Hefei, Jiaxing, Jinan, Nanchang, Nanjing, Nanyang, Shanghai, Shenzhen, Shijiazhuang, Tianjin, Wenzhou, Xi'an, Xianyang, Xining, Zigong, Zunyi
- Age
- 55 years to 80 years
- People
- 140
- Run by
- Eli Lilly and Company
See details and how to joinNCT07571161 - No phaseTaking peopleEffects and Mechanisms of Temporal Interference Brain Stimulation on Memory Function in Preclinical Alzheimer's Disease
- Where
- Beijing, Sanya
- Age
- 60 years to 80 years
- People
- 1,200
- Run by
- Xuanwu Hospital, Beijing
See details and how to joinNCT07031687